🩸 Metabolic Health · 11 min read · Subtopic 2 of 5

Triglycerides & Remnant Cholesterol

The triglycerides line is the most honest reporter of recent metabolic behavior on the whole panel — it moves fast, responds to what you did this month, and doubles as an insulin-resistance signal. This page covers what the number actually is, the remnant particles hiding behind it, the trial evidence that lowering triglycerides is not the same as lowering risk, and the levers that move it fastest.

🔎 Evidence Snapshot ★★★☆☆ Moderate — strong epidemiology and genetics, but drug trials show triglyceride lowering is not the same as risk lowering

What the evidence supports

  • Triglycerides are the most diet- and behavior-responsive line on the panel, and they double as a metabolic-health signal.
  • Genetic analyses support a causal role for triglyceride-rich remnant particles in heart attack risk.
  • The TG/HDL ratio is a simple, validated screen for insulin resistance — a topic owned by the Insulin Resistance page.

What remains uncertain

  • Whether lowering triglycerides with drugs reduces cardiovascular events is unresolved — most fibrate trials were neutral, and REDUCE-IT's success may not be a triglyceride story.
  • How much of the triglyceride signal comes from the triglycerides themselves versus the particles carrying them is still being untangled.
  • Fasting versus non-fasting measurement remains debated in some settings, though modern guidelines accept both.

Evidence last reviewed: August 15, 2026. Conclusions may change as new research is published.

fuel in the bloodstream

What This Number Actually Is

Triglycerides are the body's fuel transport system. Dietary fat travels from the gut as chylomicrons; the liver exports its own energy surplus as VLDL particles. Both are triglyceride-rich, both get stripped of their cargo on the way to delivering energy, and both leave behind smaller, cholesterol-rich remnant particles in the process. A fasting reading mostly captures liver VLDL output; a non-fasting reading also catches the meal's traffic. That distinction matters because the evidence has shifted: non-fasting triglycerides predict cardiovascular risk as well as, or better than, fasting values (Langsted et al., Circulation, 2008), which is why many modern guidelines accept non-fasting panels. In practice, high triglycerides usually mean one of three things, often all at once: excess incoming energy (especially alcohol and refined carbohydrate), insulin resistance (the liver over-produces and under-clears), or a genetic tendency (familial hypertriglyceridemia is real, and very high values deserve medical attention in their own right).

The Metabolic Signal

The most useful thing about triglycerides is what they say about metabolism. Because the liver clears triglycerides under insulin's direction, a high fasting level is often insulin resistance echoing back from the lab — the Insulin Resistance topic owns that story in full. The shorthand version lives in the TG/HDL ratio, a screen first validated in overweight adults by McLaughlin et al. (Annals of Internal Medicine, 2003): in mg/dL units, a ratio above about 3.0 flags likely insulin resistance. The math is ten seconds: TG 150 ÷ HDL 50 = 3.0, the boundary; TG 90 ÷ HDL 60 = 1.5, comfortably below. It is a screen, not a diagnosis — it misses some cases and it is not meaningful at very low HDL or in certain populations, so treat it as a prompt to look closer, never as a verdict. The other reason triglycerides earn attention: they move fast. Someone who removes alcohol and refined carbohydrate commonly sees the line fall by a third or more within weeks — faster than any other lipid responds — which makes the speed itself diagnostic as much as therapeutic.

BandFasting triglyceridesRead
🟢 Normal Below 150 mg/dL Normal
🟡 Borderline-high 150–199 mg/dL Worth attention
🟠 High 200–499 mg/dL Act on causes
🔴 Very high 500 mg/dL and above Clinician territory

Remnant Cholesterol: The Quiet Fraction

Remnant cholesterol is the cholesterol carried by leftover particles — the VLDL and chylomicron debris left behind after triglycerides are unloaded. On a standard panel it is calculated as total cholesterol minus HDL-C minus LDL-C, and under the usual arithmetic assumptions it equals triglycerides divided by 5 in mg/dL. People who have never heard the word "remnant" are carrying the risk it describes: genetic studies from the Copenhagen group found that each 1 mmol/L (about 39 mg/dL) of genetically elevated remnant cholesterol carried a substantially larger risk of myocardial infarction than the observational association suggested — roughly a 2.8-fold increase per mmol/L in the genetic analysis (Varbo et al., Journal of the American College of Cardiology, 2013; Jørgensen et al., European Heart Journal, 2013). The interpretation: the remnant–heart-disease link is causal, not a bystander effect of other risk factors. That is the entire rationale for the non-HDL shortcut: non-HDL-C folds remnants into the count while LDL-C quietly leaves them out. In practical terms, triglycerides of 200 mg/dL mean roughly 40 mg/dL of remnant cholesterol — a number that, per the genetic evidence, is already doing causal work before anyone flags the panel as abnormal.

The Trial Ledger: Lowering TG Is Not the Same as Lowering Risk

The chart below tells an uncomfortable story. REDUCE-IT found that icosapent ethyl — a purified prescription EPA — reduced major cardiovascular events by about 25% in high-risk people with elevated triglycerides already on statins (Bhatt et al., NEJM, 2019), but the benefit is unlikely to be explained by triglyceride lowering alone, and the trial's placebo-arm quirks keep the interpretation contested. FIELD and ACCORD found fenofibrate trends or no added benefit on top of statins (Keech et al., The Lancet, 2005; Ginsberg et al., NEJM, 2010). PROMINENT, the cleanest test yet, lowered triglycerides substantially with pemafibrate and produced no reduction in events (Das Pradhan et al., NEJM, 2022) — strong evidence that the triglyceride number is a marker of the problem rather than the whole problem. For prevention, the levers that work are behavioral; for very high values, the immediate concern is pancreatitis, not just atherosclerosis.

Triglyceride-Lowering Trials vs. Events
Four major trials of triglyceride-lowering drugs in high-risk populations. Bar lengths are illustrative of outcome results, not effect sizes: only REDUCE-IT clearly reduced events.
Icosapent ethyl (REDUCE-IT) −25% events Fenofibrate (FIELD) trend only Fenofibrate (ACCORD) no benefit Pemafibrate (PROMINENT) neutral

⚠️ When triglycerides stop being a signal and start being a danger

Fasting triglycerides at or above 500 mg/dL — and especially the 880–1000+ range — carry a rising pancreatitis risk, and can reflect familial chylomicronemia rather than lifestyle. Diet tweaks are not the plan at that altitude: this is prompt-medical-attention territory, and any medication discussion belongs with a clinician, not a supplement aisle.

The Levers That Actually Move It

A Month of Subtraction, Worked

March panel: triglycerides 260 mg/dL, HDL-C 41, occasional weekday beers, a sweetened-coffee habit, dinner starch portions sized by habit. April: alcohol paused, the sweetened coffees replaced, an after-dinner walk added, nothing else heroic. May panel: triglycerides 155, HDL-C 45. The person changed no prescription and cut no meal they loved — they subtracted the three inputs that most reliably feed liver VLDL output. That is the triglyceride story in one data point: a line that answers within weeks to subtraction and movement, which makes it the panel's fastest feedback loop. Two caveats keep it honest: a single low reading on one good month settles nothing (trends do), and the same interventions barely move LDL or ApoB — those lines answer to different levers, on their own pages.

TG ÷ 5
The remnant-cholesterol estimate in mg/dL, hiding inside every standard panel
≥500
Fasting triglycerides (mg/dL) where pancreatitis risk becomes the headline concern
−25%
Event reduction in REDUCE-IT — the one positive result in the trial ledger

Triglyceride Questions, Answered Briefly

The Bottom Line

  1. Triglycerides are a metabolic signal first — insulin resistance's echo and the panel's most behavior-responsive line.
  2. Remnants are the hidden load: roughly TG ÷ 5 in mg/dL, genetically causal for heart attacks, and invisible in the LDL-C number.
  3. The drug trials disagree: only REDUCE-IT clearly reduced events — the triglyceride number is a marker of the problem, not the whole problem.
  4. The levers are subtraction and movement: alcohol out, refined carbs down, exercise in — expect movement within weeks, and treat ≥500 mg/dL as clinician territory.

Related Topics

Sources & further reading